A Phase 2 interventional study of BPL-003 in Alcohol Use Disorder, sponsored by Beckley Psytech Limited. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Beckley Psytech Limited (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Alcoholism with a site in United Kingdom — 8 open to participants now, 9 under way, 2 of them phase 3. Alcoholism · United Kingdom.
Among the 33 studies in Alcoholism with a site in United Kingdom, this one is the 27th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 2, and was the 24th registered.
1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.
Browse Alcoholism studies →8 of the 33 studies in Alcoholism with a site in United Kingdom are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United Kingdom, United States, Belgium and 5 more countries
Ages 18–75
Eli Lilly and Company · Sites in United Kingdom, United States, Belgium and 5 more countries
Ages 18–75
University of Cambridge · Sites in United Kingdom
Ages 18–60
King's College London · Sites in United Kingdom
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 5 · Phase 4 2
First in 2003; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 88 across 1,430 interventional studies indexed under Alcoholism.
Median enrollment 56 across the 29 interventional studies, 1,331 across the 4 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beckley Psytech Limited, one of the names counted as Eli Lilly and Company. Under that name alone:
Beckley Psytech Limited is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Eli Lilly and Company has 7 studies filed under Alcoholism — fewer than ten, so there is no comparison to draw.
1 of the studies in Alcoholism with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07341230University of CambridgeDeep Brain Stimulation to Understand and Treat Addiction | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies in Alcoholism with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An open-label, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological support, to explore the potential effects on alcohol use and related symptoms in patients with Alcohol Use Disorder.
Approximately 12 eligible participants will be receive a single dose of BPL-003, given intranasally, with 12 weeks of follow-up assessments. Psychological support will be given before, during and after dosing
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BPL-003
A single dose administered intranasally
Percentage of Participants With Treatment Emergent Adverse Events
The number (%) of participants with at least one treatment-emergent adverse event is presented. More detailed information is provided in the dedicated 'Adverse Events' section
Time frame: Up to 12 weeks
Percentage of Participants With Clinically Significant Abnormal Laboratory Tests
The number (%) of participants with any clinically significant abnormal laboratory tests (routine haematology, clinical chemistry and coagulation) is presented
Time frame: Up to 12 weeks
Percentage of Participants With Clinically Significant Abnormal Vital Signs
The number (%) of participants with any clinically significant abnormal vital signs (blood pressure, heart rate and temperature) result is presented
Time frame: Up to 12 weeks
Number of Participants With Post-baseline Suicidal Ideation or Behaviour Based on C-SSRS Score
The C-SSRS was performed at screening, on Day 0 (dosing day), and on Days 1, 7, and 84 post-dose. Participants were counted if they answered 'yes' to any question. At baseline, the C-SSRS assessed the worst-point suicidal ideation experienced during the participant's lifetime. Beyond baseline, suicidal ideation and behaviour since last visit was assessed.
Time frame: Up to 12 weeks
Time to Readiness for Discharge Post-dose Using the Readiness for Discharge Questionnaire (RDQ)
The RDQ was a brief assessment scale to ensure that ahead of discharge after BPL-003 dosing, participants: * Were fully responsive, aware of their surroundings, and reacted adequately * The acute psychedelic effects of the drug had completely subsided * Were fully orientated (name, location, time) * Had normal (or only slightly elevated) blood pressure and pulse rate, and normal breathing frequency and body temperature * Had a stable gate, normal muscle coordination, and could walk safely * Had only mild to moderate potential side affects that did not need to be medically monitored * Had no acute suicidal ideations or suicidal intentions * Possible distress or feelings of overwhelm had sufficiently subsided and the participant felt safe to be discharged. Readiness for discharge was assessed at 90 minutes post-dose and then every 30 minutes until the participant was deemed ready for discharge (eg, the answer was 'yes' to all of the above items).
Time frame: 1 Day
Percentage of Participants With Occurrence of Reactivation Using the Reactivation Questionnaire (ReAQ)
The occurrence and (if applicable) frequency, emotional valence, and functional impact of any reactivation events was determined. To determine if reactivation had occurred, participants were asked if they had any flashbacks or recurrence of any effects of the study drug experience.
Time frame: Up to 12 weeks
Effects on the Mystical Experience Questionnaire (MEQ-30)
The MEQ-30 was performed to assess the extent of a participant's mystical experience after receiving BPL-003 on Day 0 (dosing day). The questionnaire comprises a list of 30 phenomena, with subscales to measure mystical, positive mood, transcendence of space and time, and ineffability factors, measured on a 0 to 5 scale (0=none; not at all to 5=extreme). A 'total MEQ-30 score' was calculated for each participant as the average of all their responses. The total MEQ-30 score is presented. The higher the score, the greater the mystical experience. A total score of ≥3 was considered to be a significant mystical experience.
Time frame: 1 Day
Effects on the Ego Dissolution Inventory (EDI)
The EDI was performed to assess the extent of a participant's dissolution of ego after receiving BPL-003 on Day 0 (dosing day). The inventory comprises 8 statements. Participants rated their agreement to each statement by marking on a visual analogue scale from 0 ("no, not more than usually") to 100 ("yes, entirely or completely"). Higher scores are indicative of more intense ego dissolution. In practice, this means participants with higher scores could have a reduced sense of having a distinct, separate self; greater feelings of unity with the environment or universe; a loss of self-referential thoughts or identity; or altered boundaries between 'self' and 'other'. A 'total EDI score' was calculated for each participant as the average of their individual-item scores. The total EDI score is presented.
Time frame: 1 Day
Percentage of Participants With a Complete Mystical Experience Using the MEQ-30
The MEQ-30 was performed to assess the extent of a participant's mystical experience after receiving BPL-003 on Day 0 (dosing day). The questionnaire comprises a list of 30 phenomena, with subscales to measure mystical, positive mood, transcendence, and ineffability factors, measured on a 0 to 5 scale (0=none; not at all to 5=extreme). A 'total MEQ-30 score' was calculated for each participant as the average of all their responses. A complete mystical experience was defined as reaching or exceeding a score of 3 on all four sub-domains (mystical, positive mood, transcendence of time and space, and ineffability) of the MEQ-30 scale.
Time frame: 1 Day
Percentage of Participants Experiencing an Ego Dissolution Using the EDI
The EDI was performed to assess the extent of a participant's dissolution of ego after receiving BPL-003 on Day 0 (dosing day). The inventory comprises 8 statements. Participants rated their agreement to each statement by marking on a visual analogue scale from 0 ("no, not more than usually") to 100 ("yes, entirely or completely"). Participants were classed as experiencing an ego dissolution if they had a total score of \>50.0 out of 100 on the EDI scale.
Time frame: 1 Day
Description of the BPL-003 Subjective Experience Data, From a Qualitative Interview
After BPL-003 dosing, participants had the option to participate in a one-to-one guided interview with independent researchers trained in microphenomenology methods to describe their psychedelic experience. Temporal aspects of drug effects (e.g., sensory, cognitive, metacognitive, and sense of self/other/connectedness) were elicited through open-ended interview questions.
Time frame: Interviews were conducted approximately 2 hours after dosing
Feedback From Therapists on the Frequency and Duration of Psychotherapy Sessions, Therapy Manual and Overall Therapy Model
Key themes from qualitative feedback on the treatment model was sought from therapists on frequency and duration of psychotherapy sessions, implementation of therapy manual, and overall therapy model. Feedback was obtained in a qualitative interview with each therapist after each participant's last integration session (between Day 15 and Day 42).
Time frame: 1 Day
Semi-structured Interview to Assess Psychological Changes Following BPL-003 Treatment
After BPL-003 dosing, participants had the option to participate in a semi-structured interview. The interviews were topic-guided, qualitative interviews to understand psychological changes shortly after dosing on Day 1, and on Day 84.
Time frame: Up to 12 weeks
Timeline Follow-Back (TLFB) Interview to Assess the Percentage of Abstinent Days (PAD)
Using the TLFB interview, the PAD in the 85 days before Day -3 (or start of detox) vs the PAD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.
Time frame: Up to 12 weeks
TLFB Interview to Assess the Percentage of Heavy Drinking Days (PHDD)
Using the TLFB interview, the PHDD in the 85 days before Day -3 (or start of detox) vs PHDD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.
Time frame: Up to 12 weeks
TLFB Interview to Assess the Percentage of Drinking Days (PDD)
Using the TLFB interview, the PDD in the 85 days before Day -3 (or start of detox) vs PDD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.
Time frame: Up to 12 weeks
Participants were recruited to the study between 29 March 2023 and 02 July 2024 from community treatment services for addiction, or by community advertisement.
| Milestone | BPL-003 Arm |
|---|---|
| Started | 13 |
| Completed | 12 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
The number (%) of participants with at least one treatment-emergent adverse event is presented. More detailed information is provided in the dedicated 'Adverse Events' section
| Participants | BPL-003 Arm |
|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events | 11 |
The number (%) of participants with any clinically significant abnormal laboratory tests (routine haematology, clinical chemistry and coagulation) is presented
| Participants | BPL-003 Arm |
|---|---|
| Percentage of Participants With Clinically Significant Abnormal Laboratory Tests | 0 |
The number (%) of participants with any clinically significant abnormal vital signs (blood pressure, heart rate and temperature) result is presented
| Participants | BPL-003 Arm |
|---|---|
| Percentage of Participants With Clinically Significant Abnormal Vital Signs | 4 |
The C-SSRS was performed at screening, on Day 0 (dosing day), and on Days 1, 7, and 84 post-dose. Participants were counted if they answered 'yes' to any question. At baseline, the C-SSRS assessed the worst-point suicidal ideation experienced during the participant's lifetime. Beyond baseline, suicidal ideation and behaviour since last visit was assessed.
| Participants | BPL-003 Arm |
|---|---|
| Number of Participants With Post-baseline Suicidal Ideation or Behaviour Based on C-SSRS Score | 1 |
The RDQ was a brief assessment scale to ensure that ahead of discharge after BPL-003 dosing, participants: * Were fully responsive, aware of their surroundings, and reacted adequately * The acute psychedelic effects of the drug had completely subsided * Were fully orientated (name, location, time) * Had normal (or only slightly elevated) blood pressure and pulse rate, and normal breathing frequency and body temperature * Had a stable gate, normal muscle coordination, and could walk safely * Had only mild to moderate potential side affects that did not need to be medically monitored * Had no acute suicidal ideations or suicidal intentions * Possible distress or feelings of overwhelm had sufficiently subsided and the participant felt safe to be discharged. Readiness for discharge was assessed at 90 minutes post-dose and then every 30 minutes until the participant was deemed ready for discharge (eg, the answer was 'yes' to all of the above items).
| Hours | BPL-003 Arm |
|---|---|
| Time to Readiness for Discharge Post-dose Using the Readiness for Discharge Questionnaire (RDQ) | 2.1 (1.4 to 3.8) |
The occurrence and (if applicable) frequency, emotional valence, and functional impact of any reactivation events was determined. To determine if reactivation had occurred, participants were asked if they had any flashbacks or recurrence of any effects of the study drug experience.
| Participants | BPL-003 Arm |
|---|---|
| Percentage of Participants With Occurrence of Reactivation Using the Reactivation Questionnaire (ReAQ) | 0 |
The MEQ-30 was performed to assess the extent of a participant's mystical experience after receiving BPL-003 on Day 0 (dosing day). The questionnaire comprises a list of 30 phenomena, with subscales to measure mystical, positive mood, transcendence of space and time, and ineffability factors, measured on a 0 to 5 scale (0=none; not at all to 5=extreme). A 'total MEQ-30 score' was calculated for each participant as the average of all their responses. The total MEQ-30 score is presented. The higher the score, the greater the mystical experience. A total score of ≥3 was considered to be a significant mystical experience.
| score on 0 to 5 scale | BPL-003 Arm |
|---|---|
| Total MEQ-30 score | 3.07 (0.63 to 4.67) |
| Mystical subdomain score | 2.60 (0.40 to 4.60) |
| Positive mood subdomain score | 3.50 (1.00 to 4.67) |
| Transcendence of time and space subdomain score | 3.92 (0.67 to 5.00) |
| Ineffability subdomain score | 3.84 (1.00 to 5.00) |
The EDI was performed to assess the extent of a participant's dissolution of ego after receiving BPL-003 on Day 0 (dosing day). The inventory comprises 8 statements. Participants rated their agreement to each statement by marking on a visual analogue scale from 0 ("no, not more than usually") to 100 ("yes, entirely or completely"). Higher scores are indicative of more intense ego dissolution. In practice, this means participants with higher scores could have a reduced sense of having a distinct, separate self; greater feelings of unity with the environment or universe; a loss of self-referential thoughts or identity; or altered boundaries between 'self' and 'other'. A 'total EDI score' was calculated for each participant as the average of their individual-item scores. The total EDI score is presented.
| Total score on 0 to 100 scale | BPL-003 Arm |
|---|---|
| Effects on the Ego Dissolution Inventory (EDI) | 52.4 (6 to 82) |
The MEQ-30 was performed to assess the extent of a participant's mystical experience after receiving BPL-003 on Day 0 (dosing day). The questionnaire comprises a list of 30 phenomena, with subscales to measure mystical, positive mood, transcendence, and ineffability factors, measured on a 0 to 5 scale (0=none; not at all to 5=extreme). A 'total MEQ-30 score' was calculated for each participant as the average of all their responses. A complete mystical experience was defined as reaching or exceeding a score of 3 on all four sub-domains (mystical, positive mood, transcendence of time and space, and ineffability) of the MEQ-30 scale.
| Participants | BPL-003 Arm |
|---|---|
| Percentage of Participants With a Complete Mystical Experience Using the MEQ-30 | 4 |
The EDI was performed to assess the extent of a participant's dissolution of ego after receiving BPL-003 on Day 0 (dosing day). The inventory comprises 8 statements. Participants rated their agreement to each statement by marking on a visual analogue scale from 0 ("no, not more than usually") to 100 ("yes, entirely or completely"). Participants were classed as experiencing an ego dissolution if they had a total score of \>50.0 out of 100 on the EDI scale.
| Participants | BPL-003 Arm |
|---|---|
| Percentage of Participants Experiencing an Ego Dissolution Using the EDI | 7 |
After BPL-003 dosing, participants had the option to participate in a one-to-one guided interview with independent researchers trained in microphenomenology methods to describe their psychedelic experience. Temporal aspects of drug effects (e.g., sensory, cognitive, metacognitive, and sense of self/other/connectedness) were elicited through open-ended interview questions.
| Participants | BPL-003 Arm |
|---|---|
| Sensory domain [body effect]: unusual physical sensations | 5 |
| Sensory domain [body effect]: Not feeling the body | 5 |
| Sensory domain [time perception]: lost sense of time or time felt shorter/longer | 8 |
| Cognition domain [insight/meaning]: Insights, personal meaning at the peak of the experience | 6 |
| Cognition domain [control/letting go]: Actively doing something (e.g., asking existential questions) | 7 |
| Metacognition domain [meta-awareness of emotions]: Thoughts about feelings | 5 |
| Metacognition domain [monitoring own thoughts]: Tracking content and frequency of thoughts | 6 |
| Metacognition domain [metacognitive control]: Emotional regulation | 7 |
| Self/Others/Connectedness domain [cognitive self-consciousness]: No/minimal sense of self | 5 |
| Self/Others/Connectedness domain [spatial self-consciousness]: Loss of sense of space | 7 |
Key themes from qualitative feedback on the treatment model was sought from therapists on frequency and duration of psychotherapy sessions, implementation of therapy manual, and overall therapy model. Feedback was obtained in a qualitative interview with each therapist after each participant's last integration session (between Day 15 and Day 42).
| Participants | BPL-003 Arm |
|---|---|
| A shift in perspective, inducing reflection and disruption of habitual processes | 4 |
| Increases in self-compassion and acceptance | 4 |
| Reappraisal of identity, core beliefs and values | 3 |
| Facing fears and overcoming adversity | 3 |
Using the TLFB interview, the PAD in the 85 days before Day -3 (or start of detox) vs the PAD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.
| % of abstinent days | BPL-003 Arm |
|---|---|
| PAD 85 days prior to Day -3 | 33.15 ± 22.80 |
| PAD at Day 14 | 89.88 ± 24.26 |
| PAD at Day 28 | 88.69 ± 20.93 |
| PAD at Day 56 | 83.78 ± 25.56 |
| PAD at Day 84 | 80.84 ± 28.23 |
Using the TLFB interview, the PHDD in the 85 days before Day -3 (or start of detox) vs PHDD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.
| % of heavy drinking days | BPL-003 Arm |
|---|---|
| PHDD 85 days prior to Day -3 | 56.24 ± 26.39 |
| PHDD at Day 14 | 6.55 ± 18.39 |
| PHDD at Day 28 | 8.04 ± 17.70 |
| PHDD at Day 56 | 11.31 ± 21.28 |
| PHDD at Day 84 | 13.19 ± 21.84 |
Using the TLFB interview, the PDD in the 85 days before Day -3 (or start of detox) vs PDD post-dosing measured on Days 14, 28, 56, and 84 were determined to assess alcohol use.
| % of drinking days | BPL-003 Arm |
|---|---|
| PDD 85 days prior to Day -3 | 66.85 ± 22.80 |
| PDD at Day 14 | 10.12 ± 24.26 |
| PDD at Day 28 | 11.31 ± 20.93 |
| PDD at Day 56 | 16.22 ± 25.56 |
| PDD at Day 84 | 19.16 ± 28.23 |
After BPL-003 dosing, participants had the option to participate in a semi-structured interview. The interviews were topic-guided, qualitative interviews to understand psychological changes shortly after dosing on Day 1, and on Day 84.
| Participants | BPL-003 Arm |
|---|---|
| Day 1: Reset, release, or rebirth experience | 6 |
| Day 1: Increased acceptance, improved emotional processing and connection | 5 |
| Day 84: Reappraisal of self and relationship with alcohol | 8 |
| Day 84: Improved awareness, cognitive flexibility, and acceptance | 6 |
| Day 84: Increased self-compassion, improved relationships, and connections | 7 |
| Day 84: Improved wellbeing, sleep, and energy levels | 6 |
Collected over Treatment-emergent adverse events were recorded throughout the study (from informed consent until end of follow-up, up to 16 weeks overall). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BPL-003 Arm | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Event | BPL-003 Arm |
|---|---|
| Administration site painGeneral disorders | 4/13 |
| Blood pressure increasedInvestigations | 4/13 |
| NightmarePsychiatric disorders | 2/13 |
| FlashbackPsychiatric disorders | 2/13 |
| VomitingGastrointestinal disorders | 2/13 |
| DissociationPsychiatric disorders | 1/13 |
| Sleep disorderPsychiatric disorders | 1/13 |
| AgitationPsychiatric disorders | 1/13 |
| AnxietyPsychiatric disorders | 1/13 |
| Depersonalisation/derealisation disorderPsychiatric disorders | 1/13 |
Data from all enrolled participants is presented.
| Age, Continuous(Years) | BPL-003 Arm |
|---|---|
| Mean | 49.3 ± 10.77 |
| Sex: Female, Male(Participants) | BPL-003 Arm |
|---|---|
| Female | 3 |
| Male | 10 |
| Race (NIH/OMB)(Participants) | BPL-003 Arm |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 12 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | BPL-003 Arm |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 12 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | BPL-003 Arm |
|---|---|
| United Kingdom | 13 |
| Number of participants with any lifetime suicidal ideation or behaviour based on C-SSRS score(Participants) | BPL-003 Arm |
|---|---|
| Count of participants | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion.
Ran from May 2023 to primary completion in Oct 2024, 16 months.
Results were first posted in May 2026, 1 year 7 months after primary completion.
Of 134 phase 2 interventional studies under Alcoholism, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BPL-003